Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | GCK | P35557 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 2/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | PLA2G7 | Q13093 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6425726 | 0.87 | CYP19A1 (0.50) | CYP19A1ALDH1A1HPGDARPDE4B | |
| SCHEMBL6424091 | 0.87 | CYP19A1 (0.50) | CYP19A1ALDH1A1HPGDARPDE4B | |
| SCHEMBL5185726 | 0.86 | EPAS1 (0.50) | EPAS1GCKARSLC22A12SLC6A4 | |
| SCHEMBL7268296 | 0.84 | PDE4B (0.51) | CYP19A1ALDH1A1HPGDARPDE4B | |
| SCHEMBL1377229 | 0.82 | CYP19A1 (0.62) | CYP19A1ALDH1A1HPGDARPDE4B | |
| SCHEMBL9472016 | 0.82 | CYP19A1 (0.62) | CYP19A1ALDH1A1HPGDARPDE4B | |
| SCHEMBL31403095 | 0.81 | EPAS1 (0.54) | EPAS1SLC22A12SLC6A4PLA2G7 | |
| SCHEMBL10051874 | 0.81 | EPAS1 (0.55) | EPAS1 | |
| SCHEMBL29390509 | 0.80 | CYP19A1 (0.65) | CYP19A1ALDH1A1HPGDARPDE4B | |
| SCHEMBL4581525 | 0.80 | CYP19A1 (0.65) | CYP19A1ALDH1A1HPGDARPDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110461814-B | Resin blends, prepregs and articles containing a phthalonitrile reactive diluent and a bisphthalonitrile resin | 3M创新有限公司 | 2023-04-14 | — | — | CN | disclosed |
| US-11292891-B2 | Resin blends containing a phthalonitrile reactive diluent and a diphthalonitrile resin, prepregs, and articles | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2022-04-05 | — | — | US | disclosed |
| US-20200131336-A1 | RESIN BLENDS CONTAINING A PHTHALONITRILE REACTIVE DILUENT AND A DIPHTHALONITRILE RESIN, PREPREGS, AND ARTICLES | 3M INNOVATIVE PROPERTIES COMPANY | 2020-04-30 | — | — | US | disclosed |
| EP-3601215-A1 | RESIN BLENDS CONTAINING A PHTHALONITRILE REACTIVE DILUENT AND A DIPHTHALONITRILE RESIN, PREPREGS, AND ARTICLES | 3M Innovative Properties Company (US) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018175025-A1 | RESIN BLENDS CONTAINING A PHTHALONITRILE REACTIVE DILUENT AND A DIPHTHALONITRILE RESIN, PREPREGS, AND ARTICLES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2018-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131336-A1 | RESIN BLENDS CONTAINING A PHTHALONITRILE REACTIVE DILUENT AND A DIPHTHALONITRILE RESIN, PREPREGS, AND ARTICLES | PNN, RPN1, DCXR | EPAS1 2088/4885CYP19A1 3498/4885ALDH1A1 720/4885 |
| US-11292891-B2 | Resin blends containing a phthalonitrile reactive diluent and a diphthalonitrile resin, prepregs, and articles | PNN, RPN1, DCXR | EPAS1 2088/4885CYP19A1 3498/4885ALDH1A1 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.